Shares of Orthopediatrics Corp (NASDAQ:KIDS) have been assigned an average recommendation of “Buy” from the six ratings firms that are presently covering the firm, MarketBeat.com reports. One analyst has rated the stock with a sell rating, one has issued a hold rating and four have assigned a buy rating to the company. The average 1-year target price among brokerages that have updated their coverage on the stock in the last year is $47.00.

KIDS has been the topic of a number of research reports. Needham & Company LLC set a $69.00 target price on shares of Genomic Health and gave the stock a “buy” rating in a research report on Wednesday, June 19th. BidaskClub lowered shares of Ames National from a “hold” rating to a “sell” rating in a research report on Wednesday. BTIG Research reduced their target price on shares of Verastem to $8.00 and set a “buy” rating on the stock in a research report on Friday, May 10th. Finally, Zacks Investment Research lowered shares of Hess Midstream Partners from a “hold” rating to a “sell” rating in a research report on Tuesday, May 14th.

NASDAQ:KIDS traded down $0.93 on Friday, reaching $34.83. The stock had a trading volume of 57,833 shares, compared to its average volume of 106,890. The firm has a market cap of $524.89 million, a P/E ratio of -36.28 and a beta of 0.14. Orthopediatrics has a 1-year low of $25.11 and a 1-year high of $47.82. The company has a debt-to-equity ratio of 0.26, a current ratio of 8.60 and a quick ratio of 6.01. The stock’s fifty day simple moving average is $38.96.

Orthopediatrics (NASDAQ:KIDS) last released its quarterly earnings results on Wednesday, May 8th. The company reported ($0.21) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.17) by ($0.04). Orthopediatrics had a negative net margin of 16.71% and a negative return on equity of 16.43%. The firm had revenue of $14.66 million during the quarter, compared to analyst estimates of $14.67 million. As a group, equities analysts anticipate that Orthopediatrics will post -0.45 EPS for the current year.

Several hedge funds have recently made changes to their positions in the company. RTW Investments LP bought a new stake in shares of Orthopediatrics during the fourth quarter worth approximately $7,848,000. Prospect Capital Advisors LLC bought a new stake in shares of Orthopediatrics during the fourth quarter worth approximately $7,136,000. American Century Companies Inc. bought a new stake in shares of Orthopediatrics during the fourth quarter worth approximately $3,880,000. BlackRock Inc. raised its stake in shares of Orthopediatrics by 12.4% during the fourth quarter. BlackRock Inc. now owns 455,657 shares of the company’s stock worth $15,894,000 after buying an additional 50,179 shares during the last quarter. Finally, FMR LLC raised its stake in shares of Orthopediatrics by 8.6% during the fourth quarter. FMR LLC now owns 414,600 shares of the company’s stock worth $14,462,000 after buying an additional 33,000 shares during the last quarter. Institutional investors own 48.63% of the company’s stock.

Orthopediatrics Company Profile

OrthoPediatrics Corp., a medical device company, designs, develops, and markets anatomically appropriate implants and devices for the treatment of children with orthopedic conditions in the United States and internationally. The company's products comprise PediLoc, PediPlates, cannulated screws, PediFlex nail, PediNail products, PediLoc tibia products, anterior cruciate ligament reconstruction systems, locking cannulated blades, locking proximal femurs, RESPONSE Spine systems, Bandloc, and Pediguard.

Featured Story: What is a dead cat bounce?

Receive News & Ratings for Orthopediatrics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Orthopediatrics and related companies with MarketBeat.com's FREE daily email newsletter.